AgenTus is working to discover and develop CAR and TCR based living drugs and advance them towards the clinic to treat patients with solid tumors and hematologic cancers.

Our pipeline of living drugs is guided by the following attributes:

Living drugs for potential utility both as single agents and as components of combination regimens.
Best-in-class treatment options for a large number of patients afflicted with a variety of cancers.
Multi-platform approaches to generate clinical candidates with optimal pharmacologic features.

Currently, candidate selection is underway for our lead programs.

Back to Top